Editas Medicine, Inc. — Director's Dealing 2018

Mar 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2018-03-16

Reporting Person: Hack Andrew A. F. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-16	Common Stock	M	6000	$6.48	Acquired	6000	Direct
2018-03-16	Common Stock	S	6000	$39.43	Disposed	0	Direct
2018-03-19	Common Stock	M	6000	$6.48	Acquired	6000	Direct
2018-03-19	Common Stock	S	6000	$37.65	Disposed	0	Direct
2018-03-20	Common Stock	M	5000	$6.48	Acquired	5000	Direct
2018-03-20	Common Stock	S	5000	$37.51	Disposed	0	Direct
2018-03-20	Common Stock	M	1000	$6.48	Acquired	1000	Direct
2018-03-20	Common Stock	S	1000	$38.39	Disposed	0	Direct
2018-03-20	Common Stock	M	22000	$24.6	Acquired	22000	Direct
2018-03-20	Common Stock	S	22000	$37.91	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-16	Stock Option (right to buy)	$6.48	M	6000	Disposed	2025-09-13	Common Stock (6000)	Direct
2018-03-19	Stock Option (right to buy)	$6.48	M	6000	Disposed	2025-09-13	Common Stock (6000)	Direct
2018-03-20	Stock Option (right to buy)	$6.48	M	6000	Disposed	2025-09-13	Common Stock (6000)	Direct
2018-03-20	Stock Option (right to buy)	$24.60	M	22000	Disposed	2027-02-28	Common Stock (22000)	Direct

Footnotes

F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017.

F2: This transaction was executed in multiple trades at prices ranging from $39.02 to $40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $37.29 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $37.13 to $38.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $38.23 to $38.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: This transaction was executed in multiple trades at prices ranging from $37.86 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7: This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.

F8: This amount includes an additional 2,851 option shares relating to the portion of this award constituting an Incentive Stock Option that the Reporting Person inadvertently omitted in that Form 4 filed by the Reporting Person with the SEC on February 16, 2018.

F9: This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021.